Amgen/AZ's brodalumab AMAGINEs bright future in psoriasis
This article was originally published in Scrip
Executive Summary
Amgen and AstraZeneca look set to dominate the emerging anti-IL17 field after their investigational product brodalumab trounced a key rival Stelara (ustekinumab) in a head-to-head Phase III trial in moderate-to-severe plaque psoriasis. But the key question remains as to how its side-effect profile will shape up once the full data are available.